Ilex/Millennium Campath
Executive Summary
The user fee deadline for chronic lymphocytic leukemia treatment Campath is May 19, Ilex reports, after FDA accepts response to Feb. 20 "complete review" letter. Phase IV study of Campath (alemtuzumab) vs. alkylating agent chlorambucil is under discussion with FDA. The trial design and final labeling negotiations are the only remaining issues for approval (1"The Pink Sheet" Feb. 26, In Brief)
You may also be interested in...
Ilex/Millennium Campath
Design of post-approval commitment trial under discussion with FDA following receipt of "complete review" letter for the chronic lymphocytic leukemia treatment, Millennium reports. Campath is on track for approval in first quarter, the company says. FDA's Oncologic Drugs Advisory Committee voted 14-1 in favor of accelerated approval of alemtuzumab but was undecided on the design of the post-approval comparative study (1"The Pink Sheet" Dec. 18, 2000, p. 17)
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: